BioTime, Inc. (NYSEMKT:BTX) Files An 8-K Other Events

BioTime, Inc. (NYSEMKT:BTX) Files An 8-K Other Events
Item 8.01 – Other Events

Story continues below

On March 16 and 17, 2017 the European Patent Office (EPO) Opposition division issued oral decisions upholding two key patents licensed to our subsidiary Cell Cure Neurosciences Ltd. (“Cell Cure”). The patents protect Cell Cure’s lead product OpRegen® which is currently in a Phase I/IIa clinical trial for the treatment of the dry form of age related macular degeneration (AMD). A large pharmaceutical company and an anonymous filer challenged the EPO’s previous grant of two European patents (EP2554661 and EP2147094), both entitled, “Stem Cell-Derived Retinal Pigment Epithelial Cells,” which cover the proprietary directed differentiation methods to produce the pluripotent stem cell-derived retinal pigment epithelial (RPE) cells that comprise OpRegen®.

Section 7 – Regulation FD

Item 7.01 – Regulation FD Disclosure

On March 28, 2017, we issued the press release attached to this report as Exhibit 99.1. The content of this Item 7.01 and Exhibit 99.1 shall be deemed “furnished” and not “filed” under Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any filing made by BioTime under the Securities Act of 1933, as amended, or the Exchange Act except as may be expressly set forth by specific reference in such filing.

Item 9.01 – Financial Statements and Exhibits

Exhibit Number Description 99.1 Press Release dated March 28, 2017


About BioTime, Inc. (NYSEMKT:BTX)

BioTime, Inc. is a clinical-stage biotechnology company. The Company is focused on the field of regenerative medicine, specifically pluripotent stem cell technology. The Company is engaged in the research and development of therapeutic products for oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer, and hydrogel products that may be used in surgery and products for human embryonic stem cell research. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The Company’s pluripotent stem cell technology is complemented by its HyStem technology for the delivery and engraftment of cells, whether derived from pluripotent stem cells or the patient’s own somatic or adult stem cells, at the desired location.

BioTime, Inc. (NYSEMKT:BTX) Recent Trading Information

BioTime, Inc. (NYSEMKT:BTX) closed its last trading session up +0.07 at 3.26 with 204,331 shares trading hands.

An ad to help with our costs